Haemonetics (HAE)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-09
$103.16+0.31%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Haemonetics grows revenue 3-6% yearly as guided. Profit margins aim to expand 50-100 basis points. Free cash flow remains strong near $210 million annually. The stock trades cheap with a PE of 15 versus peers at 30.
Profit margins fell 50 basis points last quarter. Free cash flow dropped 53% year over year. Revenue growth could slow below 3% if demand weakens. Valuation may stay low if execution falters.
The market prices about 6% revenue growth and values the stock 29% below our fair value. Our fair value is 38% above the Street median, reflecting confidence in margin and cash flow recovery.
Breaks if: Free cash flow conversion falls significantly below 80% in FY27
Breaks if: Operating margin declines or fails to expand by at least 50 bps in FY27
Organic revenue growth falls below 3% in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable, long-term thesis with a focus on consistent revenue growth. HAE has demonstrated strong recent financial performance, but the overall earnings quality is fragile, suggesting caution in the multi-year view.
The market appears to price in a neutral valuation relative to peers, with some expectations of growth. The current valuation reflects a slight premium compared to its industry counterparts, indicating that investors expect HAE to maintain its competitive position.
Management is on track to achieve its organic revenue growth target of 4-7% for fiscal 2027, supported by a strong first quarter. However, operating margin expansion is lagging behind expectations, which could impact overall profitability if not addressed.
The long-term thesis hinges on management's ability to sustain revenue growth while improving operating margins. Additionally, external factors such as sector performance and economic conditions will play a critical role in determining HAE's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the thesis. Additionally, raised guidance aims to expand organic revenue by 3-6% for fiscal 2027. There are no new threats identified that could weaken this outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1-3 years, HAE's performance will depend on its execution of growth strategies and external market conditions. Not investment advice.